MIF

Macrophage migration inhibitory factor · P14174 · MIF on Sugi Atlas →

68,591 patent compounds predicted against MIF, 40,477 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
Benzyl Isothiocyanate (SCHEMBL44145)	1.00	13/20
SCHEMBL126040	0.63	13/20
SCHEMBL31015	0.61	13/20
SCHEMBL41756	0.64	12/20
Phenethylisothiocyanate (SCHEMBL156960)	1.00	11/20
SCHEMBL106506	0.56	11/20
SCHEMBL207554	0.57	8/20
Phenethyl Isocyanate (SCHEMBL5918)	0.63	7/20
SCHEMBL103400	0.72	6/20
SCHEMBL7988	0.53	6/20
SCHEMBL44496	0.52	6/20
Phenylhexyl Isothiocyanate (SCHEMBL7809)	1.00	5/20
SCHEMBL37883	0.73	5/20
Drinidene (SCHEMBL121997)	0.62	5/20
SCHEMBL41909	0.57	5/20
Sulforaphane (SCHEMBL105202)	0.45	5/20
Sulforaphane (SCHEMBL105203)	0.45	5/20
SCHEMBL7765	0.34	5/20
1-Phenylethyl Isothiocyanate (SCHEMBL156959)	1.00	4/20
SCHEMBL7808	0.67	4/20

Clinical trials — most relevant to MIF by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Efficacy of Ibuprofen Chronotherapy in Healing After Surgical Extraction of the Mandibular Third Molar	PHASE2/PHASE3	UNKNOWN
Neoadjuvant Aitua (PD-1/CTLA-4 Bispecific) Plus Nab-Paclitaxel and Carboplatin for Advanced High-Grade Serous Ovarian Cancer	PHASE2	NOT_YET_RECRUITING
Efficacy and Safety of Oral Immunotherapy With GcMAF in Hospitalized Patients With COVID-19 Pneumonia	PHASE2	COMPLETED
Pembrolizumab Plus Enfortumab Vedotin in Collecting Duct and Renal Medullary Carcinoma	PHASE2	RECRUITING
Pembrolizumab/Lenvatinib With and Without Healthy Donor FMT (hdFMT) in Relapsed/ Refractory (R/R) Melanoma	PHASE2	WITHDRAWN
Intranasal Inhalations of Bioactive Factors Produced by M2 Macrophages in Patients With Organic Brain Syndrome	PHASE1/PHASE2	COMPLETED
IRon Nanoparticle Enhanced MRI in the Assessment of Myocardial infarctioN	PHASE2	COMPLETED
Alrizomadlin (APG-115) in Subjects With BAP1 Cancer Syndrome and Early-Stage Mesothelioma	PHASE2	WITHDRAWN
Part 2 of Phase 1 Study of GC1008 to Treat Advanced Melanoma (Part 2 Will Only Accept and Treat Patients With Advanced Malignant Melanoma)	PHASE1	COMPLETED
Indicators of Neuronal Insult in Newborns of COVID-19 Positive Mothers.	nan	UNKNOWN
Macrophage Inhibitory Factor and High-Mobility Group-1 Protein in Children Undergoing Cardiopulmonary Bypass	nan	COMPLETED
Effect of Non-surgical Treatment of Periodontitis Patients Focusing on Inflammatory Mediators in Gingival Crevicular Fluid	nan	COMPLETED
The Clinical Diagnosis Meaning of MIF in Coronary Heart Disease	nan	COMPLETED
Role of Macrophage Migratory Inhibitory Factor in Systemic Sclerosis	nan	UNKNOWN
MIF Involvement in AML	nan	ACTIVE_NOT_RECRUITING
Platelet-rich Plasma and Synovial Cytokines in Knee Osteoarthritis	nan	COMPLETED
The Relation Between Macrophage Migration Inhibitory Factor (MIF) and 25(OH) Vitamin D3 Serum Levels in Rheumatoid Arthritis	nan	UNKNOWN
Biomarkers in the Evaluation of Chronic Lung Disease	nan	COMPLETED
Meteorin-like Levels in Individuals With Periodontitis	nan	COMPLETED
Soluble Factors in the Serum of Severely Burned Patients	nan	COMPLETED
The Impact of M1/M2 Tumor Associated Macrophage (TAM) Polarization on Cancer Progression and Prognosis Prediction	nan	UNKNOWN
Novel Biomarkers in Inflammatory Bowel Disease	nan	COMPLETED
COVID-19 Infection and Fetal-neonatal Outcomes	nan	UNKNOWN
Adipocytokines in Endometrial Cancer	nan	COMPLETED
Correlation Between Serum Markers of Unstable Plaque and Virtual Histology of Unstable Plaque Visualized by IVUS	nan	COMPLETED
Cytokine Change in Hepatocellular Carcinoma Treated by Thermal Ablation	nan	COMPLETED
Early Regenerative Intervention for Post-Traumatic Osteoarthritis	nan	UNKNOWN
Biobehavioral-Cytokine Interactions in Ovarian Cancer	nan	COMPLETED
The Influence of Ventilation on Perioperative Neurocognitive Disorders	nan	WITHDRAWN
Can Gdf-15 Level Predict Progression to Multiple Organ Failure in Patients With Septic Shock	nan	ENROLLING_BY_INVITATION

Related proteins — ESM-2 sequence neighbours (a MIF binder may also engage these)

Protein	Name	Similarity
Q4R549	—	1.000	Q4R549 →
Q6DN04	—	1.000	Q6DN04 →
O55052	—	1.000	O55052 →
P30904	—	1.000	P30904 →
P34884	—	1.000	P34884 →
P80928	—	0.997	P80928 →
P80177	—	0.995	P80177 →
Q1ZZU7	—	0.995	Q1ZZU7 →
Q02960	—	0.964	Q02960 →
Q9D2R0	—	0.889	Q9D2R0 →
Q3T186	—	0.887	Q3T186 →
O46560	—	0.887	O46560 →
A3QK15	—	0.886	A3QK15 →
Q9JMI1	—	0.886	Q9JMI1 →
Q6P8M1	—	0.886	Q6P8M1 →
CTH	Cystathionine gamma-lyase	0.885	landscape →
Q71R50	—	0.885	Q71R50 →
ACMSD	2-amino-3-carboxymuconate-6-semialdehyde decarboxylase	0.884	landscape →
P36959	—	0.884	P36959 →
Q0II68	—	0.882	Q0II68 →
Q9Z244	—	0.882	Q9Z244 →
Q9DCZ1	—	0.882	Q9DCZ1 →
Q9FH13	—	0.882	Q9FH13 →
Q0II59	—	0.881	Q0II59 →
P82197	—	0.881	P82197 →
Q8K183	—	0.880	Q8K183 →
Q5NAY4	—	0.879	Q5NAY4 →
P48495	—	0.879	P48495 →
Q6UWP2	—	0.879	Q6UWP2 →
P40142	—	0.879	P40142 →